Arpeflu, 50 mg 30 pcs.

Antiviral drug, has immunomodulatory and anti-flu effects, specifically suppresses influenza viruses A and B.

It has interferon-inducing properties, stimulates humoral and cellular immune reactions, phagocytic function of macrophages, increases resistance of the body to viral infections. It prevents the development of post-flu complications, reduces the frequency of exacerbations of chronic diseases, normalizes immunological parameters.

The antiviral action is due to the suppression of the fusion of the lipid shell of the virus with the cell membranes when the virus comes into contact with the cell. Therapeutic effectiveness in influenza is shown in reduction of intoxication and severity of catarrhal symptoms, shortening of periods of fever and overall duration of the disease.

The drug is low-toxic (LD 50>4 g/kg). It does not have any negative effect on the human body when administered orally in recommended doses.

Pharmacokinetics

Absorption is fast. Rapidly distributed to organs and tissues. TCmax at a dose of 50 mg – 1.2 h, 100 mg – 1.5 h. Metabolized in the liver. T1/2 is 17-21 hours. About 40% is eliminated unchanged, mainly in bile (38.9%) and in small amount in kidney (0.12%). During the first day 90% of the administered dose is excreted.

Indications

Treatment and prevention of influenza and other acute respiratory viral infections (including those complicated by bronchitis and pneumonia); chronic bronchitis, pneumonia, recurrent herpes infection (in complex treatment); for the prevention of infectious complications and normalization of immune status in the postoperative period.

Pharmacological effect

An antiviral agent that has an immunomodulatory and anti-influenza effect, specifically suppresses influenza A and B viruses.

It has interferon-inducing properties, stimulates humoral and cellular immune responses, the phagocytic function of macrophages, and increases the body’s resistance to viral infections. Prevents the development of post-influenza complications, reduces the frequency of exacerbations of chronic diseases, and normalizes immunological parameters.

The antiviral effect is due to the suppression of the fusion of the lipid membrane of the virus with cell membranes upon contact of the virus with the cell. Therapeutic effectiveness for influenza is manifested in a decrease in intoxication and the severity of catarrhal phenomena, shortening periods of fever and the overall duration of the disease.

Refers to low-toxic drugs (LD 50>4 g/kg). Does not have any negative effects on the human body when administered orally in recommended doses.

Pharmacokinetics

Absorption is fast. Quickly distributed throughout organs and tissues. TCmax when taken at a dose of 50 mg – 1.2 hours, 100 mg – 1.5 hours. Metabolized in the liver. T1/2 – 17-21 hours. About 40% is excreted unchanged, mainly with bile (38.9%) and in small amounts by the kidneys (0.12%). During the first day, 90% of the administered dose is eliminated.

Special instructions

It does not exhibit central neurotropic activity and can be used in medical practice for preventive purposes in practically healthy individuals of various professions, including those requiring increased attention and coordination of movements (transport drivers, operators, etc.).

Active ingredient

Umifenovir

Composition

Active substance:

6-bromo-5-hydroxy-1-methyl-4-dimethylaminomethyl-2-phenylthiomethylindole-3-carboxylic acid ethyl ester hydrochloride monohydrate – 50 mg.

Contraindications

Hypersensitivity;
children’s age (up to 3 years);
the presence of diseases such as galactose intolerance, lactase deficiency, glucose-galactose malabsorption.

Side Effects

Allergic reactions.

Interaction

When prescribed with other drugs, no negative effects were noted.

Manufacturer

Lekpharm, Belarus